Dianthus Medical

Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing the next generation of antibody complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead candidate, DNTH103, is a potent and selective monoclonal antibody designed to inhibit the active form of the C1s protein in the classical complement pathway. By utilizing half-life extension technology, Dianthus aims to provide patients with a more convenient, low-volume subcutaneous self-administration option compared to existing therapies. The company is currently advancing DNTH103 through multiple Phase 2 clinical trials for indications such as generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. This selective approach is intended to preserve the lectin and alternative pathways, potentially maintaining critical immune surveillance functions.